Patents by Inventor A. John Dixon
A. John Dixon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220242954Abstract: There is disclosed compositions and methods relating to or derived from anti-PD-1 antibodies. More specifically, there is disclosed fully human antibodies that bind PD-1, PD-1-binding fragments and derivatives of such antibodies, and PD-1-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having PD-1 related disorders or conditions, including various inflammatory disorders and various cancers.Type: ApplicationFiled: December 17, 2021Publication date: August 4, 2022Inventors: Heyue Zhou, Barbara A. Swanson, John Dixon Gray, Gunnar F. Kaufmann, Edwige Gros
-
Publication number: 20220144966Abstract: The present disclosure provides anti-CD38 antigen-binding proteins such as fully human anti-CD38 IgG class antibodies each having an altered amino acid sequence in their heavy chain variable region and/or light chain variable region compared to their wild type parent antibody. The present disclosure provides engineered CD38 binding proteins, particularly anti-CD38 variant antibodies, or antigen-binding portions thereof, that specifically bind CD38, and uses thereof. The disclosed anti-CD38 antigen-binding proteins and antibodies have been engineered to exhibit improved characteristics compared to the parent antibody, such as improved binding to CD38 antigen, improved binding to CD38-expressing cells, and/or higher levels of cytotoxicity. The anti-CD38 variant antibodies can cross-react (bind) with cynomolgus CD38.Type: ApplicationFiled: March 27, 2020Publication date: May 12, 2022Applicant: Sorrento Therapeutics, Inc.Inventors: Xia Cao, Heyue Zhou, John Dixon Gray, Barbara A. Swanson
-
Patent number: 11311471Abstract: A method of treating a material, the method comprising the steps of: (1) contacting the material with a composition comprising an electrophilic species selected from aldehydes, succinimidyl esters, and mixtures thereof; (2) contacting the material with a composition comprising a chelating agent and/or a salt of an amine and/or a carboxylic acid.Type: GrantFiled: September 29, 2017Date of Patent: April 26, 2022Assignee: Innospec LimitedInventors: Nicholas John Dixon, Matthew Robert Giles, Kimberley Elizabeth Griffiths, Tony Gough, Ian Malcolm McRobbie
-
Publication number: 20220118105Abstract: There is disclosed an antibody drug conjugate (ADC) having an IgG antibody that binds to a CD38 target conjugated at a Cys site in the hinge region of an IgG antibody. There is further disclosed a method for treating multiple myeloma comprising providing an effective amount of a CD38 ADC.Type: ApplicationFiled: November 3, 2021Publication date: April 21, 2022Applicant: Sorrento Therapeutics, Inc.Inventors: Tong Zhu, Alisher Khasanov, Gang Chen, Katherine Fells, Heyue Zhou, John Dixon Gray
-
Patent number: 11304884Abstract: A method of treating a material, the method comprising contacting the material with a composition comprising an alpha-substituted aldehyde.Type: GrantFiled: April 21, 2017Date of Patent: April 19, 2022Assignee: Innospec LimitedInventors: Tony Gough, Matthew Robert Giles, Kimberley Elizabeth Griffiths, Nicholas John Dixon, Ian Malcolm McRobbie
-
Patent number: 11253453Abstract: A method of combatting colour loss from a dyed material, the method comprising contacting the material with a composition comprising an amine salt of a carboxylic acid wherein the carboxylic acid has 4 to 10 carbon atoms.Type: GrantFiled: September 29, 2017Date of Patent: February 22, 2022Assignee: Innospec LimitedInventors: Nicholas John Dixon, Matthew Robert Giles, Kimberley Elizabeth Griffiths, Tony Gough, Ian Malcolm McRobbie
-
Patent number: 11253452Abstract: A method of combating colour loss from a dyed material, the method comprising contacting the material with a composition comprising a hydroxy-substituted aldehyde.Type: GrantFiled: April 21, 2017Date of Patent: February 22, 2022Assignee: Innospec LimitedInventors: Nicholas John Dixon, Matthew Robert Giles, Kimberley Elizabeth Griffiths, Tony Gough, Ian Malcolm McRobbie
-
Patent number: 11242391Abstract: There is disclosed compositions and methods relating to or derived from anti-PD-1 antibodies. More specifically, there is disclosed fully human antibodies that bind PD-1, PD-1-binding fragments and derivatives of such antibodies, and PD-1-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having PD-1 related disorders or conditions, including various inflammatory disorders and various cancers.Type: GrantFiled: January 14, 2020Date of Patent: February 8, 2022Assignee: SORRENTO THERAPEUTICS, INC.Inventors: Heyue Zhou, Barbara A. Swanson, John Dixon Gray, Gunnar F. Kaufmann, Edwige Gros
-
Patent number: 11234917Abstract: A method of combatting colour loss from a dyed material, the method comprising the steps of: (1) contacting the material with a composition comprising an electrophilic species selected from aldehydes, succinimidyl esters, and mixtures thereof; (2) contacting the material with a composition comprising a chelating agent and/or a salt of an amine and/or a carboxylic acid.Type: GrantFiled: September 29, 2017Date of Patent: February 1, 2022Assignee: Innospec LimitedInventors: Nicholas John Dixon, Matthew Robert Giles, Kimberley Elizabeth Griffiths, Tony Gough, Ian Malcolm McRobbie
-
Publication number: 20220025054Abstract: There is disclosed compositions and methods relating to anti-VEGFR2 antibodies. More specifically, there is disclosed fully human antibodies that bind VEGFR2, VEGFR2-binding fragments and derivatives of such antibodies, and VEGFR2-binding polypeptides comprising such fragments. Further still, there is disclosed antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having various cancers.Type: ApplicationFiled: July 29, 2021Publication date: January 27, 2022Applicant: Sorrento Therapeutics, Inc.Inventors: Randy Gastwirt, Heyue Zhou, John Dixon Gray, Guodi Lu
-
Publication number: 20220025064Abstract: There is disclosed compositions and methods relating to or derived from anti-CD137 antibodies. More specifically, there is disclosed fully human antibodies that bind CD137, CD137-antibody binding fragments and derivatives of such antibodies, and CD137-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating a disease requiring either stimulation of immune responses or suppression. Diseases amenable to treatment is selected from the group consisting of cancers, autoimmune diseases and viral infections.Type: ApplicationFiled: October 12, 2021Publication date: January 27, 2022Inventors: John Dixon GRAY, Heyue ZHOU
-
Publication number: 20220002415Abstract: There is disclosed compositions and methods relating to or derived from anti-CTLA4 antibodies. More specifically, there is disclosed fully human antibodies that bind CTLA4, CTLA4-antibody binding fragments and derivatives of such antibodies, and CTLA4-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating a disease requiring either stimulation of immune responses or suppression.Type: ApplicationFiled: September 22, 2021Publication date: January 6, 2022Applicant: Sorrento Therapeutics, Inc.Inventors: John Dixon Gray, Heyue Zhou
-
Publication number: 20220002422Abstract: There is disclosed compositions and methods relating to or derived from anti-c-Met antibodies. More specifically, there is disclosed fully human antibodies that bind c-Met, c-Met-binding fragments and derivatives of such antibodies, and c-Met-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having c-Met related disorders or conditions, including various inflammatory disorders and various cancers.Type: ApplicationFiled: September 22, 2021Publication date: January 6, 2022Applicant: Sorrento Therapeutics, Inc.Inventors: Barbara A. Swanson, Heyue Zhou, Yan-Liang Zhang, Randy Gastwirt, John Dixon Gray
-
Patent number: 11191845Abstract: There is disclosed an antibody drug conjugate (ADC) having an IgG antibody that binds to a CD38 target conjugated at a Cys site in the hinge region of an IgG antibody. There is further disclosed a method for treating multiple myeloma comprising providing an effective amount of a CD38 ADC.Type: GrantFiled: June 20, 2018Date of Patent: December 7, 2021Assignee: Sorrento Therapeutics, Inc.Inventors: Tong Zhu, Alisher Khasanov, Gang Chen, Katherine Fells, Heyue Zhou, John Dixon Gray
-
Publication number: 20210369160Abstract: Methods and systems are provided for point-of-care nucleic acid amplification and detection. One embodiment of the point-of-care molecular diagnostic system includes a cartridge and an instrument. The cartridge can accept a biological sample, such as a urine or blood sample. The cartridge, which can comprise one or more of a loading module, lysis module, purification module and amplification module, is inserted into the instrument which acts upon the cartridge to facilitate various sample processing steps that occur in order to perform a molecular diagnostic test.Type: ApplicationFiled: April 14, 2021Publication date: December 2, 2021Inventors: Sayeed ANDESHMAND, Thomas H. CAULEY, III, John DIXON, David GLADE, Hédia MAAMAR, Michael John McADAMS, Dzam-Si Jesse NG, David Alexander ROLFE
-
Patent number: 11180568Abstract: There is disclosed compositions and methods relating to or derived from anti-CD137 antibodies. More specifically, there is disclosed fully human antibodies that bind CD137, CD137-antibody binding fragments and derivatives of such antibodies, and CD137-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating a disease requiring either stimulation of immune responses or suppression. Diseases amenable to treatment is selected from the group consisting of cancers, autoimmune diseases and viral infections.Type: GrantFiled: February 8, 2019Date of Patent: November 23, 2021Assignee: SORRENTO THERAPEUTICS, INC.Inventors: John Dixon Gray, Heyue Zhou
-
Publication number: 20210330787Abstract: There is disclosed compositions and methods relating to or derived from anti-PD-L1 antibodies. More specifically, there is disclosed fully human antibodies that bind PD-L1, PD-L1-binding fragments and derivatives of such antibodies, and PD-L1-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having PD-L1 related disorders or conditions, including various inflammatory disorders and various cancers.Type: ApplicationFiled: May 3, 2021Publication date: October 28, 2021Applicant: Sorrento Therapeutics, Inc.Inventors: Heyue Zhou, Randy Gastwirt, Barbara A. Swanson, John Dixon Gray, Gunnar F. Kaufmann
-
Patent number: 11155628Abstract: There is disclosed compositions and methods relating to or derived from anti-c-Met antibodies. More specifically, there is disclosed fully human antibodies that bind c-Met, c-Met-binding fragments and derivatives of such antibodies, and c-Met-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having c-Met related disorders or conditions, including various inflammatory disorders and various cancers.Type: GrantFiled: June 25, 2019Date of Patent: October 26, 2021Assignee: Sorrento Therapeutics, Inc.Inventors: Barbara A. Swanson, Heyue Zhou, Yan-Liang Zhang, Randy Gastwirt, John Dixon Gray
-
Patent number: 11155623Abstract: There is disclosed compositions and methods relating to or derived from anti-CTLA4 antibodies. More specifically, there is disclosed fully human antibodies that bind CTLA4, CTLA4-antibody binding fragments and derivatives of such antibodies, and CTLA4-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating a disease requiring either stimulation of immune responses or suppression.Type: GrantFiled: January 8, 2019Date of Patent: October 26, 2021Assignee: Sorrento Therapeutics, Inc.Inventors: John Dixon Gray, Heyue Zhou
-
Patent number: 11111304Abstract: There is disclosed compositions and methods relating to anti-VEGFR2 antibodies. More specifically, there is disclosed fully human antibodies that bind VEGFR2, VEGFR2-binding fragments and derivatives of such antibodies, and VEGFR2-binding polypeptides comprising such fragments. Further still, there is disclosed antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having various cancers.Type: GrantFiled: April 7, 2015Date of Patent: September 7, 2021Assignee: Sorrento Therapeutics, Inc.Inventors: Randy Gastwirt, Heyue Zhou, John Dixon Gray, Guodi Lu